The following is an excerpt.
Only a couple of years ago, people were amazed at the idea of genetically testing a fetus using no more than a pin-prick of the mother’s blood. Suddenly, the tests have become big business:Illumina recently paid almost half a billion dollars to acquireVerinata, one of at least four companies selling fetal tests, withSequenom, Ariosa and Natera. Perhaps as a sign of the money to be made, lawsuits have beenflying among them. The talk is now of the tests’ scope being determined not by the technology but by the market for it.
View the original article here: How Soon Is Now? Prenatal Tests Racing from Theory to Practice